BioLineRxが米国預託証券およびワラントの引受公募を発表

AsiaNet 77342 （0183）

【テルアビブ（イスラエル）2019年2月5日PR Newswire＝共同通信JBN】腫瘍学と免疫学に重点を置いた臨床段階のバイオ医薬品会社であるBioLineRx Ltd.（NASDAQ/TASE: BLRX）は5日、米国預託証券（ADS）の引受公募を開始したと発表した。各ADSは、ADSを購入するワラントと固定された組み合わせで一緒に販売される。この公募に含まれるすべての有価証券はBioLineRxにより売却される。公募は市場の状況に左右され、公募が完了するかどうか、いつ完了するか、または公募の実際の規模または条件に関して保証することはできない。

BioLineRxは、提案された公募からの純調達資金を、運転資金や臨床試験資金を含む可能性があるが、これに限らない一般的な企業目的に使用することを見込んでいる。

Oppenheimer & Co. Inc.が今回の公募の唯一の売り出し幹事を務める。

上述の証券は、証券取引委員会（SEC）に提出し、有効と宣言された発行登録書（File No. 333-222332（https://c212.net/c/link/?t=0&l=en&o=2365765-1&h=2200036669&u=https%3A%2F%2Fwww.sec.gov%2Fcgi-bin%2Fbrowse-edgar%3Faction%3Dgetcompany%26filenum%3D333-222332%26owner%3Dexclude%26count%3D40&a=333-222332 ））に従って発行される。いかなる提案も目論見書の補足および有効な登録書の一部をなす添付目論見書によってのみ行われる。当該募集に関連する仮目論見書の補足および添付目論見書はSECに提出され、SECのウェブサイトwww.sec.gov で入手可能となる。仮目論見書の補足および添付目論見書のコピーは入手可能になれば、以下から取得することもできる：

Oppenheimer & Co. Inc.

Syndicate Prospectus Department

85 Broad Street, 26th Floor

New York, New York 10004

電話 212-667-8055

電子メール EquityProspectus@opco.com

このプレスリリースは、販売申し出や、購入申し出の勧誘に当たるものではなく、また、州もしくは司法管轄地域の証券取引法に基づく登録や承認の以前のそのような申し出、勧誘、販売が違法である州や地域においては、これら証券の販売を行ってはならない。

▽BioLineRxについて

BioLineRxは腫瘍学と免疫学に重点を置いた臨床段階のバイオ医薬品会社である。同社は新規化合物をインライセンスし、それらを前臨床段階および／または臨床段階を通して開発し、そして次に高度な臨床開発および／または商品化のために製薬会社と提携する。

BioLineRxの主な治療薬候補は以下の通り：

＊BL-8040：がん治療プラットフォームで、再発/難治性急性骨髄性白血病（AML）の第2a相試験を成功裏に完了し、AML強化治療として第2b相試験の最中で、自家移植のための幹細胞動員に関する第3相試験を開始した。

＊AGI-134：多発性固形腫瘍に対して開発中の免疫療法治療薬で、最近、第1/2a相試験を開始した。

BioLineRxはさらに、イスラエル発の特定の新薬候補共同開発のためのノバルティスとの戦略提携、BL-8040とKEYTRUDA（R）（pembrolizumab）の併用を用いて膵臓がんで第2a相試験を実施するMSD（米国およびカナダではメルクとして知られている）との協力契約、および、ロシュグループの一員であるジェネンテックとの間で、複数の固形腫瘍症状およびAMLに関するいくつかの第1b/2相試験においてBL-8040とジェネンテックのatezolizumabの併用を調査する協力契約をそれぞれ結んでいる。

ソース：BioLineRx Ltd.

▽問い合わせ先

Tim McCarthy

LifeSci Advisors, LLC

+1-212-915-2564

tim@lifesciadvisors.com

Tsipi Haitovsky

Public Relations

+972-52-598-9892

tsipihai5@gmail.com

BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and Warrants

PR77342

TEL AVIV, Israel, Feb. 5, 2019 /PRNewswire=KYODO JBN/ --

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company

focused on oncology and immunology, today announced that it has commenced an

underwritten public offering of American Depositary Shares ("ADSs"),

each representing one of its ordinary shares with each ADS to be sold together in a

fixed combination with a warrant to purchase ADSs. All of the securities in the

offering are to be sold by BioLineRx.  The offering is subject to market conditions,

and there can be no assurance as to whether or when the offering

may be completed, or as to the actual size or terms of the offering.

BioLineRx anticipates using the net proceeds from the proposed offering for

general corporate purposes, which may include, but are not limited to, working

capital and funding clinical trials.

Oppenheimer & Co. Inc. is acting as sole book-running manager for the offering.

The securities described above will be issued pursuant to a shelf registration

statement (File No. 333-222332 (https://c212.net/c/link/?t=0&l=en&o=2365765-1&h=2200036669&u=https%3A%2F%2Fwww.sec.gov%2Fcgi-bin%2Fbrowse-edgar%3Faction%3Dgetcompany%26filenum%3D333-222332%26owner%3Dexclude%26count%3D40&a=333-222332 ))

that was previously filed with, and declared effective by, the Securities

and Exchange Commission ("SEC").  Any offer, if at all, will be made only by

means of a prospectus supplement and accompanying prospectus forming a part of

the effective registration statement.  A preliminary prospectus supplement and

accompanying prospectus related to the offering will be filed with the SEC and

will be available on the SEC's website located at www.sec.gov.  Copies of  the

preliminary prospectus supplement and accompanying prospectus may also be obtained,

when available, from Oppenheimer & Co. Inc., Attention:

Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004,

by telephone at 212-667-8055, or by email at EquityProspectus@opco.com.  

This press release does not constitute an offer to sell or a solicitation of an

offer to buy nor shall there be any sale of these securities in any state or

jurisdiction in which such offer, solicitation or sale would be unlawful prior

to registration or qualification under the securities laws of any such state or jurisdiction.

About BioLineRx

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and

immunology. The Company in-licenses novel compounds, develops them through

pre-clinical and/or clinical stages, and then partners with pharmaceutical

companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy

platform, which has successfully completed a Phase 2a study for

relapsed/refractory acute myeloid leukemia ("AML") and is in the midst of a

Phase 2b study as an AML consolidation treatment and has initiated a Phase 3

study in stem cell mobilization for autologous transplantation; and AGI-134,

an immunotherapy treatment in development for multiple solid tumors, which has

recently initiated a Phase 1/2a study. In addition, BioLineRx has a strategic

collaboration with Novartis for the co-development of selected Israeli-sourced

novel drug candidates; a collaboration agreement with MSD (known as Merck in

the United States and Canada), on the basis of which the Company is conducting

a Phase 2a study in pancreatic cancer using the combination of BL-8040 and

KEYTRUDA(R) (pembrolizumab), and a collaboration agreement with Genentech Inc.,

a member of the Roche Group, to investigate the combination of BL-8040 and

Genentech's atezolizumab in several Phase 1b/2 studies for multiple solid tumor

indications and AML.

Various statements in this release concerning BioLineRx's future expectations

constitute "forward-looking statements" within the meaning of the Private

Securities Litigation Reform Act of 1995. These statements include words such

as "may," "expects," "anticipates," "believes," and "intends," and describe

opinions about future events. These forward-looking statements involve known

and unknown risks and uncertainties that may cause the actual results,

performance or achievements of BioLineRx to be materially different from any

future results, performance or achievements expressed or implied by such

forward-looking statements. Some of these risks are: changes in relationships

with collaborators; the impact of competitive products and technological

changes; risks relating to the development of new products; and the ability to

implement technological improvements. These and other factors are more fully

discussed in the "Risk Factors" section of BioLineRx's most recent annual

report on Form 20-F filed with the Securities and Exchange Commission on March

6, 2018 and BioLineRx's other filings with the Securities and Exchange Commission.

In addition, any forward-looking statements represent BioLineRx's views

only as of the date of this release and should not be relied upon as representing

its views as of any subsequent date. BioLineRx does not assume any

obligation to update any forward-looking statements unless required by law.

SOURCE  BioLineRx Ltd.

CONTACT: Tim McCarthy, LifeSci Advisors, LLC, +1-212-915-2564,

tim@lifesciadvisors.com; or Tsipi Haitovsky, Public Relations,

+972-52-598-9892, tsipihai5@gmail.com